News by community
10.01.2020 ADC Therapeutics Appoints Joseph Camardo, MD, as Head of Medical Affairs
Lausanne, Switzerland, January 10, 2020 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors, today announced the appointment of Joseph Camardo, MD, as Head of Medical Affairs. Dr. Camardo will develop and implement post-approval research, education and physician support activities to ensure optimal medical impact for loncastuximab tesirine (ADCT-402) for patients with B-cell non-Hodgkin lymphoma.
“We are thrilled to welcome Joe to ADC Therapeutics’ senior management team and look forward to his leadership and insights as we embark on an exciting year, during which we will submit a BLA to the U.S. Food and Drug Administration for loncastuximab tesirine, conduct launch readiness activities and continue advancing our pipeline of novel ADCs,” said Chris Martin, Chief Executive Officer of ADC Therapeutics.